Background: Poor oral health (OH) is a risk factor for systemic disease and lower quality of life (QoL). Patients with inflammatory dermatologic/rheumatologic diseases report more oral discomfort, dry mouth, and periodontal disease than controls. Medications used to treat these conditions can also adversely affect OH.
Objectives: The aim was to assess the OH of patients with chronic inflammatory dermatologic/rheumatologic diseases treated with systemic/biologic therapy, compared to controls.
Methods: Patients with chronic inflammatory dermatologic/rheumatologic diseases treated with systemic/biologic therapy were recruited from outpatient clinics across two university hospitals. All patients had a standardized World Health Organisation OH assessment performed consisting of an OH exam and questionnaire. Age- and sex-matched controls without chronic inflammatory disease were recruited from a pigmented lesion clinic. Charts of patients with chronic inflammatory dermatologic/rheumatologic diseases were reviewed to assess OH documentation.
Results: One hundred patients were examined (50 cases and 50 controls). Patients with inflammatory dermatologic/rheumatologic diseases (cases) had poorer periodontal status (mean loss of attachment 6.9 mm vs. 1.9 mm controls, = 0.01), more missing teeth (mean 7.7 vs. 4.4 controls, = 0.029), more dry mouth (82% vs. 20% controls, = 0.001), and less frequent tooth brushing (60% vs. 80% controls, = 0.037). Of 250 patient charts which were reviewed, 98.4% ( = 246) had no documentation of OH.
Conclusion: Patients with severe inflammatory dermatologic/rheumatologic conditions have poorer OH and OH-related QoL. Clinicians should appreciate the risk of poor OH in this cohort and have a low threshold for involving OH professionals in care pathways for severe inflammatory disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892474 | PMC |
| http://dx.doi.org/10.1002/ski2.156 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Psoriasis as a Systemic Disease.
Dtsch Arztebl Int
July 2024
Psoriasis Centre at the Department of Dermatology, Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel; Department of Dermatology and Allergology, Biederstein, Technical University of Munich; Department of Dermatology, Venereology, Allergology, University Hospital Essen, University Duisburg-Essen, Essen; Rheumatology center of the Ruhr area, Ruhr-University Bochum, Herne.
Article Synopsis
- Psoriasis is now recognized as a systemic disease, known as psoriatic disease, affecting not just the skin but also the joints, arteries, and bones, as supported by recent research across various medical fields.
- Key risk factors include obesity, which heightens the chance of developing psoriatic arthritis, while triggers can include stress, infections, and certain medications; associated health issues can include hypertension and depression.
- Modern treatments now focus on targeting the underlying inflammatory processes with biologics, and a structured management approach is recommended to help healthcare providers and patients collaborate on the best treatment strategies.
Background: Poor oral health (OH) is a risk factor for systemic disease and lower quality of life (QoL). Patients with inflammatory dermatologic/rheumatologic diseases report more oral discomfort, dry mouth, and periodontal disease than controls. Medications used to treat these conditions can also adversely affect OH.
View Article and Find Full Text PDFA multidisciplinary care unit approach for the management of psoriatic arthritis: an Italian experience.
Ital J Dermatol Venerol
October 2022
Unit of Rheumatology, Internal Medicine, AOSG San Giuseppe Moscati, Avellino, Italy.
Background: Psoriatic arthritis (PsA) is a chronic inflammatory disease that can produce disabling joint symptoms, adding significantly to the physical and psychosocial burden of psoriasis. Early detection is important to allow the development of an appropriate care plan to delay the onset of PsA and maximize the patient's quality of life. Our aim was to present the criteria, based on evidence and expert opinion, for a multidisciplinary approach to the management of PsA in a patient already characterized by skin manifestation.
View Article and Find Full Text PDFEarly predictors of psoriatic arthritis: a Delphi-based consensus from Italian dermatology centers.
Ital J Dermatol Venerol
June 2022
Unit of Dermatology, IRCCS Humanitas Clinic, Rozzano, Milan, Italy.
Background: Psoriatic arthritis (PsA) is an inflammatory condition which can affect up to 41% of psoriatic patients [1]. In 40-60% of patients, PsA can determine cartilage destruction and joint deformities, hereby heavily impacting physical function and quality of life, even increasing the risk of death compared to the general population [1]. PsA manifestations usually develop after psoriasis onset; therefore, dermatologists play a crucial role in the detection of early signs of arthritis.
View Article and Find Full Text PDFPDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue.
Int J Mol Sci
June 2017
Laboratory of Gastrointestinal Immunopathology, Humanitas Clinical and Research Center, Milan 20089, Italy.
Background: In the last few decades, a better knowledge of the inflammatory pathways involved in the pathogenesis of Inflammatory Bowel Disease (IBD) has promoted biological therapy as an important tool to treat IBD patients. However, in spite of a wider spectrum of biological drugs, a significant proportion of patients is unaffected by or lose their response to these compounds, along with increased risks of infections and malignancies. For these reasons there is an urgent need to look for new pharmacological targets.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!